Vaccine Patents Waiver

Baroness Chakrabarti Excerpts
Monday 24th January 2022

(2 years, 10 months ago)

Lords Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Asked by
Baroness Chakrabarti Portrait Baroness Chakrabarti
- Hansard - -

To ask Her Majesty’s Government what plans they have to support a vaccine patents waiver at the World Trade Organisation.

Lord Grimstone of Boscobel Portrait The Minister of State, Department for Business, Energy and Industrial Strategy and Department for International Trade (Lord Grimstone of Boscobel) (Con)
- Hansard - - - Excerpts

My Lords, the waiver proposal of the World Trade Organization goes beyond patents and vaccines, encompassing most intellectual property on all Covid 19-related products and technologies, with no geographical or duration limits. While HM Government remain open to initiatives that help with vaccine production and distribution, there is no evidence that waiving intellectual property protections would advance these objectives. We must focus on actions that will make a real difference, including delivering and administering vaccines globally.

Baroness Chakrabarti Portrait Baroness Chakrabarti (Lab)
- Hansard - -

I am grateful to the Minister for that, but he will understand that my Question is in the context of a previous prime ministerial promise and an obvious logical need to vaccinate the planet. The UK is paying the highest recorded price for the Pfizer vaccine. What work are Her Majesty’s Government doing to encourage Pfizer to share its necessary technology—not just the recipe—with the 100 potential mRNA manufacturers in Africa, Asia and Latin America identified by Médecins Sans Frontières and Human Rights Watch? They could be producing these vaccines now.

Lord Grimstone of Boscobel Portrait Lord Grimstone of Boscobel (Con)
- Hansard - - - Excerpts

My Lords, we are still learning about coronavirus and about how to respond effectively to its mutations. One thing that we do know is that continued innovation by companies such as Pfizer is required to enable scientists to continue to develop health products and technologies, including vaccines to help tackle the virus.